The US FDA approved Eli Lilly's Inluriyo-Verzenio combination on Sept. 18, giving adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer a new treatment option after at least one hormone therapy has stopped working.
The decision matters now because Lilly said the pills are already available in the United States. Inluriyo is a daily pill that blocks and breaks down estrogen receptors, while Verzenio is taken twice a day to slow cancer-cell division. Together, they are aimed at patients whose disease has worsened after hormone treatment, a group that often needs another option quickly once the cancer starts moving again.
The approval rests on a late-stage study of 159 patients. Those who took both drugs went a median of 11.1 months before their cancer worsened, compared with 5.5 months for patients who took Inluriyo alone. That gap is the heart of the regulatory case for the combination: it suggests the added drug delayed progression by several months in a mutation-defined group where treatment choices are narrower.
The broader setting also helps explain the decision. About half of patients with ER-positive, HER2-negative metastatic breast cancer develop an ESR1 mutation during or after treatment with hormone-blocking therapies, and that mutation can help the cancer resist treatment. The US FDA had already approved Inluriyo in September last year for metastatic breast cancer with ESR1 mutations, so the new clearance builds on an existing drug rather than introducing a completely new regimen.
The combination is not a simple gain without cost. It carries risks including severe diarrhea, low white blood cell counts, lung inflammation, liver problems and blood clots. Inluriyo's label also includes a warning for embryo-fetal toxicity, which means the new option comes with the same kind of careful trade-off that often follows advances in advanced breast cancer: longer control for some patients, but a closer watch for serious side effects.
For patients in the United States with this mutation-defined disease, the question is no longer whether the combination can be used. It can. The real issue is how quickly oncologists and patients decide that the extra months before progression are worth the added toxicity, and whether the regimen becomes a standard choice for this specific group after hormone therapy fails.
